文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

靶向多黏菌素B血液灌流对脓毒性休克伴内毒素活性升高患者28天死亡率的影响:EUPHRATES随机临床试验

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在脓毒性休克且内毒素活性测定≥0.60的患者中,多黏菌素B血液灌流联合常规治疗较假灌流联合常规治疗未降低28天死亡率。

EUPHRATES为多中心随机临床试验,纳入450例脓毒性休克且内毒素活性测定水平≥0.60的成人危重症患者,在北美55家三级医院于2010年9月至2016年6月入组。干预组接受两次多黏菌素B血液灌流(每次90-120分钟)加标准治疗并在入组24小时内完成,对照组接受假灌流加标准治疗。主要终点28天死亡率在全人群(37.7% vs 34.5%;RD 3.2%,95%CI -5.7%至12.0%;RR 1.09,95%CI 0.85-1.39;P=0.49)及MODS>9人群(44.5% vs 43.9%;RD 0.6%,95%CI -10.8%至11.9%;RR 1.01,95%CI 0.78-1.31;P=0.92)均无显著差异。结论认为在脓毒性休克伴高内毒素活性患者中,多黏菌素B血液灌流联合常规治疗较假灌流联合常规治疗未降低28天死亡率。

要点

  • 全人群28天死亡率:多黏菌素B血液灌流组84/223(37.7%)vs 假灌流组78/226(34.5%),RD 3.2%(95%CI -5.7%至12.0%),RR 1.09(95%CI 0.85-1.39),P=0.49,无显著差异。
  • MODS>9人群28天死亡率:治疗组65/146(44.5%)vs 假灌流组65/148(43.9%),RD 0.6%(95%CI -10.8%至11.9%),RR 1.01(95%CI 0.78-1.31),P=0.92,无显著差异。
  • 严重不良事件共264例,治疗组65.1% vs 假灌流组57.3%;最常见为脓毒症恶化(10.8% vs 9.1%)和脓毒性休克恶化(6.6% vs 7.7%)。
  • 纳入标准为脓毒性休克且内毒素活性测定水平≥0.60的成人危重症患者;干预为入组24小时内完成两次多黏菌素B血液灌流(每次90-120分钟)。
  • 该试验不支持在脓毒性休克伴内毒素活性升高患者中常规使用多黏菌素B血液灌流以降低28天死亡率。

适用人群与场景

  • 成人危重症患者,脓毒性休克且内毒素活性测定水平≥0.60,于2010年9月至2016年6月在北美55家三级医院入组。
  • 纳入450例,平均年龄59.8岁,女性177例(39.3%),平均APACHE II评分29.4(范围0-71,评分越高病情越重)。

诊断标准与关键阈值

  • 脓毒性休克且内毒素活性测定水平≥0.60。
  • 多器官功能障碍评分(MODS)>9作为预设亚组。

处置流程与药物剂量

  • 干预组:在入组24小时内完成两次多黏菌素B血液灌流,每次90-120分钟,联合标准治疗(n=224)。
  • 对照组:假灌流联合标准治疗(n=226)。

研究设计与关键结果

  • 多中心随机临床试验,纳入450例脓毒性休克且内毒素活性≥0.60的成人危重症患者,在北美55家三级医院入组;449例(99.8%)完成研究。
  • 主要终点28天死亡率全人群:治疗组84/223(37.7%)vs 假灌流组78/226(34.5%);RD 3.2%(95%CI -5.7%至12.0%);RR 1.09(95%CI 0.85-1.39);P=0.49。
  • MODS>9人群28天死亡率:治疗组65/146(44.5%)vs 假灌流组65/148(43.9%);RD 0.6%(95%CI -10.8%至11.9%);RR 1.01(95%CI 0.78-1.31);P=0.92。
  • 严重不良事件共264例:治疗组65.1% vs 假灌流组57.3%;最常见为脓毒症恶化(治疗组10.8% vs 假灌流组9.1%)和脓毒性休克恶化(治疗组6.6% vs 假灌流组7.7%)。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒性休克且内毒素活性测定≥0.60的成人危重症患者中,多黏菌素B血液灌流联合常规治疗较假灌流联合常规治疗未降低28天死亡率,不支持以此为目标常规开展该治疗。
  • 严重不良事件在治疗组报告比例高于假灌流组(65.1% vs 57.3%),实施该治疗时需关注脓毒症及脓毒性休克恶化等不良事件。

指南或共识出处

  • EUPHRATES随机临床试验(ClinicalTrials.gov Identifier: NCT01046669)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes.

OBJECTIVE: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017.

INTERVENTIONS: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients).

MAIN OUTCOMES AND MEASURES: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9.

RESULTS: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P = .49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P = .92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group).

CONCLUSIONS AND RELEVANCE: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01046669.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018. PMID: 30304428. doi:10.1001/jama.2018.14618

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。